In The News: School of Integrated Health Sciences
Clinical experts have published the first set of clinical guidelines for appropriately using the newly approved Alzheimer’s drug aducanumab — brand name Aduhelm.
Treatment of early Alzheimer’s patients with Biogen’s new drug Aduhelm should closely resemble how the drug was studied in its pivotal clinical trials, according to new recommendations from a panel of neuroscience experts led by UNLV’s Jeffrey Cummings.
How do you get to the Olympics? Practice, practice, practice...
A group of six leading Alzheimer’s experts have convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.
Here’s a look at what The Conversation, a non-profit source of explanatory journalism from experts in academia, is offering today.
How do you get to the Olympics? Practice, practice, practice…
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.
Women were more likely to develop lung cancer than men, suggesting a greater sex-based vulnerability to harmful radiation.
Although meant to minimize risks to human health, the proposed new limits would still be exceeded by any conceivable near-future crewed voyage to Mars.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.
Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.